



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux / O'Donnell, Jake S.; Massi, Daniela; Teng, Michele W.L.; Mandala, Mario*. - In: SEMINARS IN CANCER BIOLOGY. - ISSN 1044-579X. - ELETTRONICO. - 48:(2018), pp. 91-103. [10.1016/j.semcancer.2017.04.015]

Availability:

The webpage <https://hdl.handle.net/2158/1129680> of the repository was last updated on 2018-06-18T05:32:04Z

Published version:

DOI: 10.1016/j.semcancer.2017.04.015

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

Conformità alle politiche dell'editore / Compliance to publisher's policies

Questa versione della pubblicazione è conforme a quanto richiesto dalle politiche dell'editore in materia di copyright.

This version of the publication conforms to the publisher's copyright policies.

La data sopra indicata si riferisce all'ultimo aggiornamento della scheda del Repository FloRe - The above-mentioned date refers to the last update of the record in the Institutional Repository FloRe

(Article begins on next page)

Accepted Manuscript

Title: PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

Authors: Jake S. O'Donnell, Daniela Massi, Michele W.L. Teng, Mario Mandala



PII: S1044-579X(17)30113-X
DOI: <http://dx.doi.org/doi:10.1016/j.semcancer.2017.04.015>
Reference: YSCBI 1327

To appear in: *Seminars in Cancer Biology*

Received date: 29-11-2016
Revised date: 13-4-2017
Accepted date: 27-4-2017

Please cite this article as: O'Donnell Jake S, Massi Daniela, Teng Michele WL, Mandala Mario. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. *Seminars in Cancer Biology* <http://dx.doi.org/10.1016/j.semcancer.2017.04.015>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

Authors: Jake S. O'Donnell^{1,2,3}, Daniela Massi⁴, Michele W.L. Teng^{1,3°}, Mario Mandala^{5*°}

Affiliations:

¹Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, 4006, Queensland, Australia.

²Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston 4006, Queensland, Australia.

³School of Medicine, The University of Queensland, Herston 4006, Queensland, Australia.

⁴Unit of Medical Oncology, Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Piazza OMS 1, 24100 Bergamo, Italy

⁵Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy

*Corresponding author: Mario Mandala, Unit of Medical Oncology, Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Piazza OMS 1, 24100 Bergamo, Italy. E-mail address: mariomandala@tin.it or mmandala@asst-pg23.it Tel: +39 (035) 2673687, Fax: +39 (035) 2674985.

° Michele W.L. Teng and Mario Mandala share senior authorship

Abstract

Cancer therapies will increasingly be utilized in combination to treat advanced malignancies so as to increase their long-term efficacy in a greater proportion of patients. In particular, much attention has focused on developing targeted therapies that inhibit the PI3K-AKT-mTOR signaling network which is dysregulated in many cancer types. In addition, there is now a growing appreciation that targeting of these pathways can impact not only on cancer cells, but also host immunity. The clinical success of cancer immunotherapies targeting T-cell immune checkpoint receptors PD-1/PD-L1 has demonstrated the importance of immunoevasion as a hallmark of cancer. In this review, we discuss how PI3K-AKT-mTOR inhibitors target cancer cell biology, attenuate immune cell effector function and modulate the tumor microenvironment. We next discuss how the immunomodulatory potential of these inhibitors can be exploited through rational combinations with immunotherapies and targeted therapies.

Keywords: PI3K, AKT, mTOR, inhibitions, targeted therapy, immunotherapy, combination therapy, tumor microenvironment, immunotherapeutic resistance.

Introduction

In the past five years, cancer immunotherapy has achieved remarkable clinical efficacy in the treatment of many advanced cancer types [1]. This success represents the culmination of two decades of key research studies and conceptual developments that have occurred in the cancer immunology field. In particular, it is now appreciated that an immune response against tumor-specific neoantigens can be generated but the efficacy of these tumor-specific T cells can be limited by the immunosuppressive microenvironment fostered by many tumors [1, 2]. To date, therapies that relieve T cell suppression such as monoclonal antibodies targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) receptor expressed on T cells or its primary ligand programmed cell death ligand 1 (PD-L1) expressed on tumors or immune cells, have demonstrated the greatest clinical benefit [3-5]. In addition, a further increase in clinical efficacy was obtained by co-targeting CTLA-4 and PD-1 in the treatment of advanced melanoma [6, 7], demonstrating multiple non-redundant immunosuppressive pathways exist in the tumor microenvironment (TME). Nevertheless, only 50% of patients responded to anti-CTLA-4 and anti-PD-1 combination treatment, and treatment is in some cases associated with severe toxicity [8]. Although single agent anti-PD-1/PD-L1 therapy have demonstrated promising clinical activity in diverse tumor types including melanoma, renal cell carcinoma and lung cancer, there are still a significant proportion of patients who display primary resistance to these therapies [5]. More recently, a proportion of melanoma patients who previously were responsive to anti-PD-1 relapsed, demonstrating that like targeted therapies, acquired resistance to immunotherapies can develop [9]. Thus, identifying strategies to further increase the efficacy of cancer immunotherapies in a wider proportion of cancer patients is a key research focus. Given the safety profile of agents targeting the PD-1/PD-L1 pathway [3, 5, 10], these agents are currently being evaluated in combination with other therapies such as targeted therapies.

The signaling network defined by the phosphoinositide 3-kinase (PI3K), AKT (also referred to as protein kinase B (PKB) [11]) and mammalian target of rapamycin (mTOR), controls most hallmarks of cancer including cell cycle, survival, metabolism, motility and genomic instability; it was this understanding that prompted the development of therapeutic reagents to inhibit this pathway in oncology [12]. It is becoming increasingly apparent that this network also regulates many features of the immunosuppressive microenvironment. Interestingly, recent data derived from clinical trials and pre-clinical mouse models suggests that therapeutic inhibition of the PI3K-AKT-mTOR signaling network may have the dual benefit of staving tumor progression by limiting proliferation, migration and survival, and also augmenting tumor immunosurveillance by preventing activation of immunosuppressive pathways and enhancing anti-tumor immune-intrinsic properties [13]. While targeted therapies can induce high initial response rates, most patients relapse due to acquired resistance [14]. In this review, we first discuss how PI3K-AKT-mTOR inhibitors not only impact directly upon cancer cells, but also have the capacity to affect immune cell effector function and to modulate the tumor microenvironment. We next discuss how PI3K-AKT-mTOR inhibitors can be rationally used in combination with immunotherapies and targeted therapies to improve outcomes for patients with a variety of cancers.

PI3K-AKT-mTOR dysregulation in cancer

Over the past 30 years, the PI3K-AKT-mTOR signaling pathway has been robustly characterized. Much is now understood regarding the molecular mechanisms by which this network regulates the activities of the cell cycle, cellular proliferation, growth, survival, protein synthesis and glucose metabolism [15, 16]. Schematically, growth factors, cytokines or chemokines can stimulate the activation of receptor tyrosine kinases (RTK). This allows for the down-stream activation of important signaling intermediates capable of activating

PI3K molecules. These kinases catalyse the conversion of phosphatidylinositol-4,5-bisphosphate (PIP₂) into phosphatidylinositol-3,4,5-trisphosphate (PIP₃) [17]. These lipid products are capable of recruiting pleckstrin homology (PH) domain-containing proteins such as AKT, mTOR complex 2 (mTORC2), and phosphoinositide-dependent kinase 1 (PDK1); the interaction of either PDK1 or mTORC2 with AKT can trigger its activation [11, 18]. Finally, AKT activates the mTOR complex 1 (mTORC1) [19], which promotes cell growth and protein synthesis (**Figure 1**) [20, 21].

Consistent with its physiological role, the PI3K-AKT-mTOR pathway has been found to be hyperactivated in many types of cancer. Overall, this pathway is dysregulated via several genetic mechanisms in approximately 30% of solid cancers (**Table 1**). As such, this represents one of the most frequently dysregulated signaling cascades in human cancers [12]. Oncogenic activation of the PI3K pathway can occur through several mechanisms such as, mutation and/or amplification of genes encoding RTKs [e.g., EGFR (*ERBB1*) and Her2 (*ERBB2*)], subunits of the PI3K (e.g., p110 α , p110 β , p85 α , and p85 β), AKT (*AKT1*), or activating isoforms of the RAS GTPases [22-24]. Additionally, components of the PI3K pathway that negatively regulate its function such as the phosphatase and tensin homologue (PTEN) are amongst the most frequently occurring tumor suppressor mutations in human cancers [25-27].

Direct effects of PI3K-AKT-mTOR inhibitors on cancer cells

In oncology, targeting of the PI3K-AKT-mTOR pathway was seen as an opportunity to overcome tumor complexity and genomic heterogeneity through a central oncogenic driver, essential to many cancers [28]. To date, there are six classes of compounds targeting the PI3K-AKT-mTOR pathway at different regulatory levels. These include mTOR inhibitors,

active site mTOR inhibitors, pan-class I PI3K inhibitors (PI3Ki), isoform-selective PI3Ki, pan-PI3K-mTOR inhibitors and AKT inhibitors (**Table 2**). These agents are currently being tested within clinical trials at different stages (**Table 3**) [29].

Rapamycin and its analogues (rapalogues) are recognized as the first generation of mTOR inhibitors which inhibit the activity of mTORC1 by binding to FRBP-12 (12 kDa FK506-binding protein; also known as FKBP1A), to form a ternary complex with mTOR [30, 31]. Rapalogues such as everolimus, temsirolimus, deforolimus, and ridaforolimus are currently undergoing a number of clinical trials for therapeutic efficacy in a variety of human malignancies [30]. To date, temsirolimus and everolimus have been FDA approved for the treatment of advanced renal cell carcinoma, subependymal giant cell astrocytoma and for progressive neuroendocrine tumors of pancreatic origin; however, only modest therapeutic effects have been observed [32, 33].

Several pan-class I PI3K inhibitors target all four class I PI3K isoforms (PI3K α , PI3K β , PI3K γ and PI3K δ) with similar potencies such as CDC-0941 [34], BKM120 [35], XL147 [36], PX-866 [37], BAY806946 [38], and CH5132799 [39]; however, all remain within clinical trials. The primary argument in support of this modality is that most cancer cells express multiple PI3K isoforms with redundant functions [40]. The main concern associated with their use, is that doses needed to fully block all class I PI3Ks for extended periods might not be well-tolerated. For example, at the concentration needed to fully inhibit PI3K using the pan-PI3K inhibitor, BKM120 (buparsilib), off-target effects upon tubulin, resulting in cellular toxicity are observed [35]. For this reason, isoform-selective PI3K inhibitors with the capacity to completely block their relevant target, while limiting toxicities associated with the use of more broad inhibition have been developed [12]. Of these, the most impressive results

have been achieved using the p110 δ -selective inhibitor, GS-1101 (idelalisib), which causes dramatic responses in chronic lymphocytic leukaemia, without any major off-target effects. As such GS-1101 has been approved as a first-in-class agent for the treatment of relapsed chronic lymphocytic leukaemia, follicular B cell non-Hodgkin's lymphoma and small lymphocytic lymphoma [41, 42].

As one of the key effector nodes in the PI3K pathway, AKT was also seen as an attractive therapeutic target. To date, two classes of pan-AKT inhibitors have been developed: i) allosteric inhibitors (e.g. MK-2206) which bind to the PH domain and prevent plasma membrane localisation, and phosphorylation at Thr308 and Ser473 by PDK1 and mTORC2, respectively; ii) adenosine triphosphate (ATP)-competitive inhibitors (e.g. AZD5363 [43], ipatasertib [GHC-0068] [44], afuresertib [45], and GSK2141795 [46]) which limit AKT kinase activity. Early phase, single-agent clinical trials with AKT inhibitors have generally shown underwhelming efficacy, as having anti-proliferative, rather than antitumor activity, with stable disease identified as the best overall response [27, 47].

Overall, few PI3K-AKT-mTOR pathway inhibitors including small molecule inhibitors and biological reagents have reached later phases of drug development and approval. This is due to a few conceptual concerns which have hindered developmental progress such as: i) the challenge of targeting enzymes utilized by tumors that are also active, and play crucial roles in the homeostasis of most tissues; ii) pathway blockade generally fails to induce cancer cell death and can lead to selection of compensatory pathways that maintain survival which can eventually restore tumor growth; iii) oncogene addition to PI3K-AKT-mTOR signaling is not absolute; iv) the delivery of suboptimal dosing schedules due to toxicity; v) the presence of compensatory pathways, such as growth factor receptor signaling, which is capable of

bypassing the effects of targeted blockade. In any case, a large number of clinical trials are ongoing evaluating PI3K-AKT-mTOR inhibitors as monotherapies or in combination with other agents in (**Table 3**). Further investigation will almost certainly be needed to determine the mechanisms of actions of these therapies, and more specifically, to investigate their immunomodulatory effects within the tumour microenvironment in order to critically plan biomarker-enriched clinical trials.

Effects of PI3K-AKT-mTOR inhibitors on the tumor microenvironment

While the therapeutic effects of PI3K-AKT-mTOR inhibition are generally underwhelming, a body of recent research suggests that they can have significant biological effects in modulating both sides of the tumor-immune interface. Inflammation, while positive in some context, is a critical component of tumor progression [48]. The tumor microenvironment contains a variety of immune cell types which can either promote or limit tumor development and progression [49]. Interestingly, the activity of most immune cell types is at least, to some extent, affected by the PI3K-AKT-mTOR pathway [50]. As such, the PI3K-AKT-mTOR pathway can regulate tumor-intrinsic and immune-intrinsic features of the immunosuppressive tumor microenvironment. For example, *PTEN*-mutations within mouse models of melanoma have been shown separately to promote the expression of immunosuppressive cytokines and chemokines such as CCL20, CXCL1, IL6 and IL-23 [51], IL-6 and IL-10 [52], and also angiogenic factors such as VEGF [53]. Encouragingly, inhibition of the PI3K pathway using the selective PI3K β (p110 β) isoform inhibitor, GSK2636771 [53], or the pan-PI3K inhibitor, LY29002 [54] in various pre-clinical tumor models, has been shown to enhance CD8⁺ T cell infiltration within tumor tissue, resulting in reduced tumor burden and significant survival benefit [53, 54]. As well as promoting tumor vascularization, VEGF is important for promoting the infiltration of regulatory immune cell

subsets including immature dendritic cells, myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs); each capable of inhibiting functional anti-tumor immune responses [55, 56]. Therefore inhibition of VEGF secretion would likely promote anti-tumor immune responses.

Additional immunosuppressive microenvironment features in the tumor such as expression of immune checkpoint ligands appear to be regulated by the PI3K-AKT-mTOR pathway under certain circumstances. A variety of human and mouse tumors lacking expression of the tumor suppressor gene *PTEN*, have been shown to over-express PD-L1 [57-60]. Although usually induced in response to inflammatory cytokines such as T cell-derived interferons (IFNs) [61], PD-L1 can also be regulated (at least at the post-transcriptional level) by the PI3K-AKT-mTOR pathway [57]. The interaction of PD-L1 with PD-1 expressed by tumor-specific T cells can induce a state of functional exhaustion in which T cell proliferation, cytokine production, and migration are significantly limited [62]. This might provide one explanation as to why *PTEN*-mutant tumors are often veritable CD8⁺ T cell deserts, and why in turn, such tumors are usually subject to poor immunological control [63]. Encouragingly, inhibition of the PI3K-AKT-mTOR pathway using either a pan-PI3K inhibitor wortmannin, pan-AKT inhibitor, MK-2206 or mTOR inhibitor, rapamycin, has been demonstrated to reduce expression of PD-L1 within *PTEN*-mutant triple-negative breast cancer cell lines *in vitro* [60]. Loss of *PTEN* within preclinical melanoma models has been demonstrated to inhibit T cell-mediated tumor killing and to decrease CD8⁺ T cell infiltration within tumor tissue, which also correlated with poor outcomes to anticancer immunotherapies [53]. By contrast, it remains unlikely that inducible expression of PD-L1 by IFNs is regulated by the PI3K-AKT-mTOR network. Indeed, patient-derived melanoma cell lines with wild type (WT) *PTEN*,

cultured in the presence of a PI3K inhibitors LY294002, BKM120, or with a dual inhibitor of both PI3K and mTOR, BEZ235, failed to attenuate PD-L1 expression level [64].

Effects of PI3K-AKT-mTOR inhibitors on immune cells

Within the tumor microenvironment, immune suppression can be mediated not only by tumor cell-intrinsic effects, but also via recruitment of regulatory immune cell subsets such as MDSCs and Tregs into the tumor [13, 65]. While inhibiting components of the PI3K-AKT-mTOR pathway has been shown to reduce expression of immunosuppressive cytokines, chemokines, and checkpoint ligands, therapies such as these may also modulate the activity and viability of immunoregulatory cell types. For example, the differentiation of MDSCs appears to be heavily regulated by AKT; its inhibition has been demonstrated to limit MDSC differentiation *in vitro*. Nevertheless, the impact of AKT inhibition on MDSC differentiation within the tumor microenvironment remains poorly understood [66]. Additionally, it has been shown that a range of chemokines activate G-protein coupled receptors, tyrosine kinase, and toll-like receptors (TLRs) which signal via PI3K γ (p110 γ) within myeloid cells to promote their infiltration into tumor tissue [67]. Genetic and pharmacological inactivation of the p110 γ was demonstrated to reduce $\alpha 4\beta 1$ integrin-mediated adhesion of MDSCs and Tregs, limiting their infiltration and in turn reduced tumor growth and metastasis in murine models of melanoma, lung, pancreatic and breast cancers. Importantly, this reduction in tumor-associated inflammation and angiogenesis occurred without affecting systemic numbers of myeloid or lymphoid cells [67]. These data strongly support the findings of others who have demonstrated in pre-clinical models of colitis-associated cancer, mice lacking functional PI3K γ (P110 γ ^{-/-}) were found to harbour significantly fewer colon neoplasm in comparison to wild type controls [68, 69].

Tregs have been understood for some time to limit the activity of anti-tumor immune responses via a number of mechanisms including the secretion of IL-10 and sequestration of IL-2 [70, 71]. Interestingly, several reports have demonstrated that the utilization of the PI3K-AKT-mTOR signaling pathway differs between regulatory and conventional T cells, such that inhibition might tip the scales away from immune suppression, in favour of anti-tumour immunity [65, 72]. Using the pan-AKT inhibitors, IC87114, wortmannin, or MK-2206, it has been shown that Tregs are preferentially susceptible to inhibition; enhancing the number of CD8⁺ T cells within tumor tissue, and improving tumor control [65]. To limit off-target effects associated with pan-inhibitors, isoform specific inhibitors of PI3K δ (p110 δ) have also been developed and shown to effectively reduce tumor burden and metastasis in murine models of melanoma, lung, breast, and pancreatic cancers [73]. Specifically, P110 δ inactivation in Tregs has been demonstrated to impair maintenance and function of Tregs in the periphery. Indeed, these cells produce less IL10, and express lower levels of CD38, despite maintenance of a Treg gene signature. Importantly, CD8⁺ T cell functions were preserved in the presence of this inhibitor [73]. Together, these data suggest that the PI3K-AKT-mTOR pathway is critical for maintaining the immunosuppressive function of Tregs, however, its precise mechanism remains to be fully characterised.

Following activation, CD8⁺ T cells differentiate into effectors that proliferate and produce effector cytokines. To meet this increased bioenergetics demands, these cells undergo metabolic re-programming from quiescent mitochondrial oxidative phosphorylation (OXPHOS) to glycolysis [74]. This switch to glycolysis is directly linked to increased effector functions and is thought to occur in response to T cell receptor (TCR)-mediated signaling via the PI3K-AKT-mTOR pathway [75]. Following a productive immune response which overtime results in a decline in cognate antigen, the conversion to memory T cells is

characterised by a shift back to mitochondrial OXPHOS, fuelled by fatty acid oxidation. Especially in the context of cancer, chronic TCR signaling can induce tumor-specific CD8⁺ T cell exhaustion. These cells upregulate PD1, which *in vitro* has been demonstrated to reduce PI3K-AKT-mTOR signaling which in turn results in decreased glycolysis [76]. Specifically, this occurred by repression of PPAR-gamma coactivator 1 α (PGC1 α) expression, which is essential for mitochondrial biogenesis and metabolic regulation. Within exhausted CD8⁺ T cells this then leads to a state of energetic insufficiency. Blockade of the PD1 pathway was shown to increase the energetic metabolism of effector T cells and to promote their effector functions [77]. Together, these data might suggest that inhibition of the AKT-PI3K-mTOR signaling pathway could have a deleterious effect on exhausted effector T cell function; however, this possibility has not been robustly explored. As such the optimal schedule of when to administer these inhibitors will have to be determined. Notwithstanding these observations, inhibition of this signaling pathway has been demonstrated to improve the development of memory CD8⁺ T cells with positive effects.

Recently it was shown that the progression-free survival of melanoma patients treated with anti-PD-1 was heavily associated with the development and persistence of memory T cells [9]. Indeed, a key feature of checkpoint inhibitors given as monotherapy is their ability to induce durable responses in ~20-40% of patients treated with anti-CTLA-4 or anti-PD-1 respectively [78, 79], in contrast with the immediate, but transient responses induced by conventional chemotherapy or by targeted therapies. The process of memory T cell differentiation appears to be influenced by a number of factors including collective input via the TCR, IL-2 and IL-12 receptors which feed signals into the PI3K-AKT-mTOR network [80]. Therefore a strong case can be made that AKT can govern the balance between terminal differentiation and the generation of CD8⁺ T cell memory. In fact, this notion has been

strongly supported by studies in which mTOR inhibition using rapamycin significantly strengthened both the quality and quantity of CD8⁺ T cells, enhancing memory T cell differentiation by promoting expansion of the memory precursor (KLRG1⁻CD127⁺) pool during the T-cell expansion phase, and accelerating memory T cell differentiation during the T-cell contraction phase [81]. Additionally, multiple studies have demonstrated in the context of cancer that inhibition of AKT can potently enhance memory T cell differentiation[82]. Mechanistically, it has been demonstrated that AKT can suppress the activity of memory-promoting transcription factors such as FOXO and TCR/LEF/ β -catenin [83]. Inhibition therefore relieves this suppression and promotes memory differentiation. In the context of chronic antigen exposure, memory precursors have demonstrated a unique susceptibility to become exhausted, this perhaps provides a reason as to why T cell memory development in the context of cancer, and in chronic infections can be stunted [84].

Therapeutic combinations to improve anti-tumor immunity

As single agent therapies, the efficacy of PI3K-AKT-mTOR inhibitors in the treatment of a variety of cancers has generally been underwhelming [12, 85]. There are several possible reasons as to why; most notably: i) administration of therapies at tolerated concentrations can fail to have biological and therapeutic efficacy; ii) these therapies are targeting a signaling pathway that is integral for the homeostasis of most tissues. For example, the PI3K-AKT-mTOR pathway is important for patterning the development and activities of lymphocytes [86, 87]; a great deal of early preclinical work conducted within this field took advantage of *in vitro* systems, or immunodeficient animal models. While such analyses might have been useful for modelling the cytostatic features of PI3K-AKT-mTOR inhibitors, they are unfortunately not useful for dissecting potentially harmful immunocidal off-target effects. More recently, these potential effects have been taken into account and it was demonstrated

quite effectively that therapies targeting PI3K γ , AKT, mTOR, or PI3K δ were capable of augmenting tumor immune surveillance without broad toxicity [65, 67, 72, 81]. Tolerability notwithstanding, generally their efficacy within preclinical models remains modest. Given their immunomodulatory capacity, it is highly likely that the full potential of PI3K-AKT-mTOR inhibitors could be best realized when used in combination therapies with either immunotherapies, or targeted therapies as discussed in the next section (**Figure 3**).

Combination with immunotherapies

It has been firmly established that the efficacy of cancer immunotherapies will depend on priming and generation of tumor neoantigen-specific T cells [88], that can migrate into tumor tissue [89], and mediate effector functions (to which tumor cells are sensitive) [62, 90], and develop stable immunological memory [9]. To achieve the most effective outcomes for patients treated with a variety of anti-cancer therapies, combination therapeutic strategies involving PI3K-AKT-mTOR inhibition may be of benefit (**Figure 2**) [1]. To enhance priming and activation of tumor antigen-specific T cells, various cancer vaccination strategies have been developed. These include more traditional approaches in which immunogenic, tumor-specific peptides are combined with adjuvant and administered systemically, as well as more innovative strategies which involve the isolation of autologous DCs and loading them with tumor antigen *ex vivo* to be administered as a cellular vaccine [91, 92]. While such strategies are capable of generating systemic, tumor-specific T cell responses, their magnitude does not necessarily correlate with tumor regression. Mechanistically, this form of resistance has in some instances been demonstrated to occur as a result of T cell resistance. Upregulation of the PI3K-AKT-mTOR network can potently induce signaling via NF- κ B, capable of driving transcription of a variety of anti-apoptotic molecules including cellular inhibitors of apoptosis (cIAPs), caspase-8/FADD (FAS-associated death domain)-like IL-1 β -converting enzyme

(FLICE), inhibitory protein (c-FLIP) and members of the Bcl-2 family such as A1/BFL1 and BCL-XL [92, 93]. By therapeutically targeting up-stream PI3K-AKT signaling, sensitivity to tumor-specific CD8⁺ T cell-mediated cytotoxicity was shown to be enhanced [92]. These data suggest that the combination of peptide vaccine with PI3K-AKT inhibition would likely improve the sensitivity of tumors to immune-mediated assault (**Figure 3**). Broader characterisation might, however, be warranted to identify whether specific genetic variations were responsible for the upregulation in AKT which could be useful for predicting outcome.

To enhance the effector function (migration, proliferation and cytotoxicity) of tumor-specific T cells, immunotherapies targeting the PD-1 and CTLA-4 immune checkpoints have demonstrated the greatest clinical benefit. The general consensus is that anti-CTLA4 therapy functions by promoting proliferation of tumor-specific CD8⁺ T cells within secondary lymphoid organs, while anti-PD1 therapy relieves exhaustion of tumor-specific CD8⁺ T cells within tumor tissue; enhancing the number and function of tumor-specific effectors [1]. Since their clinical inception, it has become apparent that therapies such as these are also often subject to primary or acquired resistance [94]. Our understanding of the mechanisms underlying resistance to these therapies is improving. Now, limited evidence suggests that defects in antigen presentation [88], T cell resistance [90], the secretion of immunosuppressive cytokines from tumor cells or immune cells, the presence and activity of MDSCs and Tregs within tumor tissue, and the failure to generate protective immunological memory can all contribute to failure to anti-cancer therapies [95]. As discussed, PI3K-AKT-mTOR inhibition can augment the secretion of immunosuppressive cytokines [51-53], the infiltration of MDSCs and Tregs into tumor tissues [67-69], and promote the development of memory T cells [9, 96]. For these reasons, it is highly likely that the combining therapeutic strategies involving PI3K-AKT-mTOR inhibition with checkpoint blockade would be effective (**Figure 3**). Importantly however, several questions remain: i) would PI3K-AKT-

mTOR inhibition complement anti-PD-1/anti-CTLA4 immunotherapies within resistant tumors in which β -catenin signaling is dysregulated? One study reported its dysregulation limited the chemotaxis of antigen presenting cells capable of priming tumor-specific immunity into tumor tissue [88], ii) it was recently shown that acquired resistance to anti-PD1 therapy can occur as a result of T cell resistance to IFN γ (due to *JAK 1* and 2 mutations) or due to defective presentation of cognate antigen (due to *β 2M* mutations) [90]. iii) Would PI3K-AKT-mTOR inhibition be useful to sensitize tumors in which acquired resistance to anti-PD1 therapy has developed to alternative immunotherapies?

Conceptual advances leading to the understanding that endogenous tumor-specific immune responses can be generated, prompted the development of immunotherapeutic strategies in which autologous T cells are isolated and expanded, or manipulated from patient *ex vivo* before reinfusion, to bolster tumor-specific immunity [97]. More traditional adoptive cell therapy (ACT) approaches involve the isolation of tumor-infiltrating lymphocytes (TILs) extracted from biopsy material [97]. One of the main features of TILs that has been associated with objective response is their long-term persistence after transfer. Unfortunately, TILs isolated from tumor material are usually terminally differentiated and unable to develop a memory phenotype [82, 98]. To overcome this limitation, AKT inhibition was shown in a mouse model of ACT, to reprogram the transcriptional profile of CD8⁺ T cells into that of memory cells. Functionally, this was shown to enhance their anti-tumor efficacy and to improve overall survival [82, 98]. More recently, ACT has been improved upon to allow for the *ex vivo* manipulation of CD8 T cells transduced with chimeric antigen receptor (CAR), specific for tumor antigens that are not restricted by MHC Class I (major histocompatibility complex I) [99]. While demonstrated to be effective in the treatment of a number of malignancies, the presence of IL-2 within *ex vivo* cultures, necessary to maintain viability,

has, paradoxically been shown to reduce CAR T cell activity [99]. Similarly, it was recently demonstrated that the efficacy of CAR T cells in the treatment of solid tumours *in vivo*, could be improved with the addition of PI3K inhibitors during *ex vivo* culturing, however, these were preliminary findings and the underlying mechanism remains to be fully elucidated [99, 100].

Combination with targeted therapies

BRAF and MEK inhibitors have demonstrated broad efficacy in treatment of *BRAF*-mutant melanoma where tumor proliferation and survival is promoted by oncogenic activation. Like inhibitors of the PI3K-AKT-mTOR signaling pathway, the efficacy of these therapies have also been shown to depend on host-derived immunity in the form of CD8⁺ T cells and also NK cells; the infiltration of which into tumour tissue is enhanced following therapy [101]. Interestingly, the efficacy of these therapies is often limited due to the development of resistance [102]. A major mechanism by which resistance develops is via activation of the PI3K-AKT-mTOR pathway [102, 103]. The combination of therapies targeting BRAF/MEK and the PI3K-AKT-mTOR pathway have demonstrated additive or synergistic efficacy. For example, vemurafenib in combination with inhibitors of mTORCs 1 and 2 has been shown to be synergistic in the treatment of BRAF-mutant melanoma (**Figure 3**) [104-106]. In addition, the efficacy of therapies which inhibit epidermal growth factor receptor (EGFR) family member signaling such as erlotinib (which targets EGFR) and lapatinib (a dual inhibitor of EGFR and Her2) has also been shown in some cases to be limited by signaling via the PI3K-AKT-mTOR network. Encouragingly, the combination of lapatinib with the AKT inhibitor MK-2206 has demonstrated efficacy in recent early phase clinical trials for treatment of various solid tumors [107].

Conclusions

The heterogeneity and adaptability of many tumors strongly supports the need to utilize robust therapies which target the disease on multiple fronts. Throughout this review, we have detailed how inhibition of components of the PI3K-AKT-mTOR network can have dichotomous functions; they can halt tumor cell proliferation, and augment tumor immune surveillance. The divergent responses to PI3K-AKT-mTOR inhibition to date have been caused by a variety of factors including cellular heterogeneity, dynamic interactions and cross-talk between different nodes of the PI3K-AKT-mTOR pathway, off-target effects upon immune cells and cellular plasticity. To release their broad potential, PI3K-AKT-mTOR inhibitors require further optimization of their dosage and scheduling with respect to their use in various combinations therapies. By defining the optimal approaches to combine PI3K-AKT-mTOR inhibitors with other cancer therapies, particularly those targeting PD-1/PD-L1, it is hoped that the rates of both primary and acquired resistance could be reduced. It is probable that such therapeutic combinations could be associated with increased risk of inducing severe immune-related adverse events (irAEs). When used as single-agents, some PI3K inhibitors including idelalisib, are associated with what appear to be mild irAEs; this is seen with increased T cell infiltration within tissues, occurs more frequently within first-line patients who are more immunocompetent, and can be alleviated by administration of steroids [108]. Additionally, biallelic loss of *PIK3CD* within humans has been associated with similar symptoms, suggesting that these are likely to be irAEs. In fact, these effects are similar to irAEs observed in response to checkpoint blockade against PD-1 and/or CTLA-4 [109]. Fortunately, such conditions are usually reversible following treatment withdrawal [109]. Moving forward, an increased understanding of the immuno-modulatory effects of PI3K-AKT-mTOR inhibitors may allow its rationale combination with other therapies to improve

clinical outcomes for patients although safety of each combination will have to be thoroughly assessed.

Acknowledgements

M.T is supported by National Research Council of Australia (NH&MRC) project grants.

J.O'D is supported by an Australian Postgraduate Award (APA). This work was supported by Fondazione Oncologica Bergamasca (MM); Ministero dell'Istruzione, dell'Università e della Ricerca, Rome (MiUR) (PRIN 2015HAJH8E) (DM) and Fondazione Ente Cassa di Risparmio di Firenze (DM).

Conflict of Interest statement

The authors declare that there are no conflicts of interest.

References

1. Smyth, M.J., et al., *Combination cancer immunotherapies tailored to the tumour microenvironment*. Nat Rev Clin Oncol, 2016. **13**(3): p. 143-158.
2. Schreiber, R.D., L.J. Old, and M.J. Smyth, *Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion*. Science, 2011. **331**(6024): p. 1565-1570.
3. Brahmer, J.R., et al., *Safety and activity of anti-PD-L1 antibody in patients with advanced cancer*. N Engl J Med, 2012. **366**(26): p. 2455-65.
4. Hodi, F.S., et al., *Improved survival with ipilimumab in patients with metastatic melanoma*. N Engl J Med, 2010. **363**(8): p. 711-23.
5. Topalian, S.L., et al., *Safety, activity, and immune correlates of anti-PD-1 antibody in cancer*. N Engl J Med, 2012. **366**(26): p. 2443-54.
6. Postow, M.A., et al., *Nivolumab and ipilimumab versus ipilimumab in untreated melanoma*. N Engl J Med, 2015. **372**(21): p. 2006-17.
7. Wolchok, J.D., et al., *Nivolumab plus Ipilimumab in Advanced Melanoma*. N. Engl. J. Med., 2013. **369**(2): p. 122-133.
8. Larkin, J., et al., *Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma*. N Engl J Med, 2015.
9. Ribas, A., et al., *PD-1 Blockade Expands Intratumoral Memory T Cells*. Cancer Immunol Res, 2016. **4**(3): p. 194-203.
10. Topalian, S.L., et al., *Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab*. J Clin Oncol, 2014.
11. Burgering, B.M. and P.J. Coffey, *Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction*. Nature, 1995. **376**(6541): p. 599-602.
12. Fruman, D.A. and C. Rommel, *PI3K and cancer: lessons, challenges and opportunities*. Nat Rev Drug Discov, 2014. **13**(2): p. 140-156.
13. Xue, G., et al., *Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy*. J Natl Cancer Inst, 2015. **107**(7).

14. Menzies, A.M. and G.V. Long, *Systemic treatment for BRAF-mutant melanoma: where do we go next?* Lancet Oncol, 2014. **15**(9): p. e371-81.
15. Vanhaesebroeck, B., L. Stephens, and P. Hawkins, *PI3K signalling: the path to discovery and understanding*. Nat Rev Mol Cell Biol, 2012. **13**(3): p. 195-203.
16. Engelman, J.A., J. Luo, and L.C. Cantley, *The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism*. Nat Rev Genet, 2006. **7**(8): p. 606-19.
17. Divecha, N. and R.F. Irvine, *Phospholipid signaling*. Cell, 1995. **80**(2): p. 269-78.
18. Franke, T.F., et al., *The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase*. Cell, 1995. **81**(5): p. 727-36.
19. Martelli, A.M., et al., *The emerging multiple roles of nuclear Akt*. Biochim Biophys Acta, 2012. **1823**(12): p. 2168-78.
20. Sarbassov, D.D., et al., *Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex*. Science, 2005. **307**(5712): p. 1098-101.
21. Inoki, K., et al., *TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling*. Nat Cell Biol, 2002. **4**(9): p. 648-57.
22. Song, X., et al., *ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas*. Cancer Res, 2015. **75**(6): p. 1035-45.
23. Karakas, B., K.E. Bachman, and B.H. Park, *Mutation of the PIK3CA oncogene in human cancers*. Br J Cancer, 2006. **94**(4): p. 455-459.
24. Yi, K.H. and J. Lauring, *Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity*. Oncotarget, 2016. **7**(4): p. 4241-51.
25. Steck, P.A., et al., *Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers*. Nat Genet, 1997. **15**(4): p. 356-62.
26. Li, J., et al., *PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer*. Science, 1997. **275**(5308): p. 1943-7.
27. Pearce, L.R., D. Komander, and D.R. Alessi, *The nuts and bolts of AGC protein kinases*. Nat Rev Mol Cell Biol, 2010. **11**(1): p. 9-22.

28. Kaneda, M.M., et al., *PI3Kgamma is a molecular switch that controls immune suppression*. Nature, 2016.
29. Engelman, J.A., *Targeting PI3K signalling in cancer: opportunities, challenges and limitations*. Nat Rev Cancer, 2009. **9**(8): p. 550-62.
30. Meng, L.H. and X.F. Zheng, *Toward rapamycin analog (rapalog)-based precision cancer therapy*. Acta Pharmacol Sin, 2015. **36**(10): p. 1163-9.
31. Cybulski, N. and M.N. Hall, *TOR complex 2: a signaling pathway of its own*. Trends Biochem Sci, 2009. **34**(12): p. 620-7.
32. Motzer, R.J., et al., *Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial*. Lancet, 2008. **372**(9637): p. 449-56.
33. Hutson, T.E., et al., *Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma*. J Clin Oncol, 2014. **32**(8): p. 760-7.
34. Sarker, D., et al., *First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors*. Clin Cancer Res, 2015. **21**(1): p. 77-86.
35. Brachmann, S.M., et al., *Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations*. Mol Cancer Ther, 2012. **11**(8): p. 1747-57.
36. Chakrabarty, A., et al., *Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors*. Cancer Res, 2013. **73**(3): p. 1190-200.
37. Ihle, N.T., et al., *Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling*. Mol Cancer Ther, 2004. **3**(7): p. 763-72.
38. Liu, N., et al., *BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models*. Mol Cancer Ther, 2013. **12**(11): p. 2319-30.
39. Ohwada, J., et al., *Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799*. Bioorg Med Chem Lett, 2011. **21**(6): p. 1767-72.

40. Foukas, L.C., et al., *Activity of any class IA PI3K isoform can sustain cell proliferation and survival*. Proc Natl Acad Sci U S A, 2010. **107**(25): p. 11381-6.
41. Brown, J.R., et al., *Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia*. Blood, 2014. **123**(22): p. 3390-7.
42. Ramanathan, S., et al., *Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib*. Clin Pharmacokinet, 2016. **55**(1): p. 33-45.
43. Tamura, K., et al., *Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors*. Cancer Chemother Pharmacol, 2016. **77**(4): p. 787-95.
44. De Bono, J.S., *Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study)*. in ASCO Annual Meeting J Clin Oncol 34, 2016 (suppl; abstr 5017).
45. Allen, C.E., et al., *Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis*. Blood, 2013. **122**(21): p. 2907-2907.
46. Dumble, M., et al., *Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor*. PLoS One, 2014. **9**(6): p. e100880.
47. Nitulescu, G.M., et al., *Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)*. Int J Oncol, 2016. **48**(3): p. 869-85.
48. Hanahan, D. and R.A. Weinberg, *Hallmarks of cancer: the next generation*. Cell, 2011. **144**(5): p. 646-74.
49. Fridman, W.H., et al., *The immune contexture in human tumours: impact on clinical outcome*. Nat Rev Cancer, 2012. **12**(4): p. 298-306.
50. Okkenhaug, K., *Signaling by the phosphoinositide 3-kinase family in immune cells*. Annu Rev Immunol, 2013. **31**: p. 675-704.
51. Ying, H., et al., *PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF- κ B–Cytokine Network*. Cancer Discovery, 2011. **1**(2): p. 158-169.
52. Dong, Y., et al., *PTEN functions as a melanoma tumor suppressor by promoting host immune response*. Oncogene, 2014. **33**(38): p. 4632-4642.

53. Peng, W., et al., *Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy*. Cancer Discovery, 2016. **6**(2): p. 202-216.
54. Dong, Y., et al., *PTEN functions as a melanoma tumor suppressor by promoting host immune response*. Oncogene, 2014. **33**(38): p. 4632-42.
55. Wada, J., et al., *The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions*. Anticancer Res, 2009. **29**(3): p. 881-8.
56. Osada, T., et al., *The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients*. Cancer Immunol Immunother, 2008. **57**(8): p. 1115-24.
57. Lastwika, K.J., et al., *Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer*. Cancer Res, 2016. **76**(2): p. 227-38.
58. Song, M., et al., *PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer*. PLoS One, 2013. **8**(6): p. e65821.
59. Parsa, A.T., et al., *Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma*. Nat Med, 2007. **13**(1): p. 84-8.
60. Mittendorf, E.A., et al., *PD-L1 expression in triple-negative breast cancer*. Cancer Immunol Res, 2014. **2**(4): p. 361-70.
61. Ribas, A., *Tumor immunotherapy directed at PD-1*. N Engl J Med, 2012. **366**(26): p. 2517-9.
62. Wherry, E.J. and M. Kurachi, *Molecular and cellular insights into T cell exhaustion*. Nat Rev Immunol, 2015. **15**(8): p. 486-499.
63. Teng, M.W., et al., *Classifying Cancers Based on T-cell Infiltration and PD-L1*. Cancer Res, 2015. **75**(11): p. 2139-45.
64. Gowrishankar, K., et al., *Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB*. PLoS One, 2015. **10**(4): p. e0123410.
65. Abu-Eid, R., et al., *Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway*. Cancer Immunol Res, 2014. **2**(11): p. 1080-9.

66. Gato-Canas, M., et al., *A core of kinase-regulated interactomes defines the neoplastic MDSC lineage*. *Oncotarget*, 2015. **6**(29): p. 27160-75.
67. Schmid, M.C., et al., *Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kgamma, a single convergent point promoting tumor inflammation and progression*. *Cancer Cell*, 2011. **19**(6): p. 715-27.
68. Gonzalez-Garcia, A., et al., *Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer*. *Gastroenterology*, 2010. **138**(4): p. 1374-83.
69. Hirsch, E., et al., *PI3K in cancer-stroma interactions: bad in seed and ugly in soil*. *Oncogene*, 2014. **33**(24): p. 3083-3090.
70. Zou, W., *Regulatory T cells, tumour immunity and immunotherapy*. *Nat Rev Immunol*, 2006. **6**(4): p. 295-307.
71. Teng, M.W., et al., *Biology and clinical observations of regulatory T cells in cancer immunology*. *Curr Top Microbiol Immunol*, 2011. **344**: p. 61-95.
72. Ali, K., et al., *Inactivation of PI(3)K p110[*dgr*] breaks regulatory T-cell-mediated immune tolerance to cancer*. *Nature*, 2014. **510**(7505): p. 407-411.
73. Patton, D.T., et al., *Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4⁺CD25⁺Foxp3⁺ regulatory T cells*. *J Immunol*, 2006. **177**(10): p. 6598-602.
74. Buck, M.D., D. O'Sullivan, and E.L. Pearce, *T cell metabolism drives immunity*. *J Exp Med*, 2015. **212**(9): p. 1345-60.
75. Chang, C.H., et al., *Posttranscriptional control of T cell effector function by aerobic glycolysis*. *Cell*, 2013. **153**(6): p. 1239-51.
76. Patsoukis, N., et al., *PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation*. *Nat Commun*, 2015. **6**: p. 6692.
77. Bengsch, B., et al., *Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion*. *Immunity*, 2016. **45**(2): p. 358-73.

78. Robert, C.R., A. Omid, H. Daud, A. Wolchok, JD. Joshua, AM. Hwu, W. Weber, JS. Gangadhar, TC. Joseph, RW. Dronca, RS. Patnaik, A. Zarour, HM. Kefford, R. Hersey, P. Li, A. Diede, SJ. Ebbinghaus, S. Hodi, FS. , *Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.*, in *2016 ASCO Annual Meeting*. 2016.
79. Schadendorf, D., et al., *Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma*. J Clin Oncol, 2015. **33**(17): p. 1889-94.
80. Kim, E.H. and M. Suresh, *Role of PI3K/Akt signaling in memory CD8 T cell differentiation*. Front Immunol, 2013. **4**: p. 20.
81. Araki, K., et al., *mTOR regulates memory CD8 T-cell differentiation*. Nature, 2009. **460**(7251): p. 108-12.
82. van der Waart, A.B., et al., *Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy*. Blood, 2014. **124**(23): p. 3490-500.
83. Lazarevic, V., L.H. Glimcher, and G.M. Lord, *T-bet: a bridge between innate and adaptive immunity*. Nat Rev Immunol, 2013. **13**(11): p. 777-89.
84. Angelosanto, J.M., et al., *Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection*. J Virol, 2012. **86**(15): p. 8161-70.
85. Yap, T.A., et al., *First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors*. J Clin Oncol, 2011. **29**(35): p. 4688-95.
86. Okkenhaug, K. and B. Vanhaesebroeck, *PI3K in lymphocyte development, differentiation and activation*. Nat Rev Immunol, 2003. **3**(4): p. 317-330.
87. Okkenhaug, K., M. Turner, and M.R. Gold, *PI3K Signaling in B Cell and T Cell Biology*. Front Immunol, 2014. **5**: p. 557.
88. Spranger, S., R. Bao, and T.F. Gajewski, *Melanoma-intrinsic [bcr]-catenin signalling prevents anti-tumour immunity*. Nature, 2015. **523**(7559): p. 231-235.
89. Tumeh, P.C., et al., *PD-1 blockade induces responses by inhibiting adaptive immune resistance*. Nature, 2014. **515**(7528): p. 568-71.

90. Zaretsky, J.M., et al., *Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma*. N Engl J Med, 2016. **375**(9): p. 819-29.
91. Timmerman, J.M. and R. Levy, *Dendritic cell vaccines for cancer immunotherapy*. Annu Rev Med, 1999. **50**: p. 507-29.
92. Noh, K.H., et al., *Activation of Akt as a mechanism for tumor immune evasion*. Mol Ther, 2009. **17**(3): p. 439-47.
93. Karin, M., et al., *NF-kappaB in cancer: from innocent bystander to major culprit*. Nat Rev Cancer, 2002. **2**(4): p. 301-10.
94. Ribas, A., et al., *Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma*. Jama, 2016. **315**(15): p. 1600-9.
95. O'Donnell, J.S., M.J. Smyth, and M.W. Teng, *Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?* Genome Med, 2016. **8**(1): p. 111.
96. Liu, J., et al., *Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease*. Cancer Discov, 2016.
97. Rosenberg, S.A. and N.P. Restifo, *Adoptive cell transfer as personalized immunotherapy for human cancer*. Science, 2015. **348**(6230): p. 62-8.
98. Crompton, J.G., et al., *Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics*. Cancer Res, 2015. **75**(2): p. 296-305.
99. Perkins, M.R., et al., *Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells*. Blood, 2015. **126**(23): p. 1893-1893.
100. Grande, S., et al., *Abstract 2296: Inhibition of the PI3K/Akt pathway during CAR T cell production results in enhanced efficacy across multiple *in vivo* tumor models*. Cancer Research, 2016. **76**(14 Supplement): p. 2296-2296.
101. Knight, D.A., et al., *Host immunity contributes to the anti-melanoma activity of BRAF inhibitors*. J Clin Invest, 2013. **123**(3): p. 1371-81.
102. Perna, D., et al., *BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model*. Proc Natl Acad Sci U S A, 2015. **112**(6): p. E536-45.

103. Shao, Y. and A.E. Aplin, *Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells*. Cancer Res, 2010. **70**(16): p. 6670-81.
104. Cooper, Z.A., et al., *Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma*. Oncoimmunology, 2014. **3**(9): p. e954956.
105. Sweetlove, M., et al., *Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth*. Front Oncol, 2015. **5**: p. 135.
106. Posch, C., et al., *Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo*. Proc Natl Acad Sci U S A, 2013. **110**(10): p. 4015-20.
107. Wisinski, K.B., et al., *Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer*. Clin Cancer Res, 2016. **22**(11): p. 2659-67.
108. O'Brien, S.M., et al., *A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia*. Blood, 2015. **126**(25): p. 2686-94.
109. Boutros, C., et al., *Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination*. Nat Rev Clin Oncol, 2016. **13**(8): p. 473-86.
110. Gao, Y., C.Y. Yuan, and W. Yuan, *Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?* Stem Cell Investig, 2016. **3**: p. 31.
111. Papadopoulos, K.P., et al., *Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors*. Clin Cancer Res, 2014. **20**(9): p. 2445-56.
112. Munster, P., et al., *First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies*. Clin Cancer Res, 2016. **22**(8): p. 1932-9.
113. Shapiro, G.I., et al., *Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors*. Clinical Cancer Research, 2014. **20**(1): p. 233-245.

114. Akinleye, A., et al., *Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics*. J Hematol Oncol, 2013. **6**(1): p. 88.
115. Burris, H.A., et al., *Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study*. Journal of Clinical Oncology, 2011. **29**(15_suppl): p. 3003-3003.
116. Tabernero, J., et al., *First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068*. Journal of Clinical Oncology, 2011. **29**(15_suppl): p. 3022-3022.
117. Banerji, U., et al., *First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors*. Journal of Clinical Oncology, 2012. **30**(15_suppl): p. 3004-3004.
118. Tabernero, J., et al., *Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies*. Cancer Research, 2012. **72**(8 Supplement): p. CT-02-CT-02.
119. Shapiro, G.I., et al., *Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors*. Clin Cancer Res, 2014. **20**(1): p. 233-45.
120. Garcia, V.M., et al., *A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma*. Journal of Clinical Oncology, 2011. **29**(15_suppl): p. 3021-3021.

Figure Legends

Figure 1. The PI3K-AKT-mTOR signaling network.

The PI3Ks are family of 8 members, grouped into three classes. In the context of cancer, four class I enzymes, termed PI3K α , PI3K β , PI3K γ and PI3K δ appear to be of significance. These are heterodimers of a 110 kDa catalytic subunit (p110 α , p110 β , p110 γ and p110 δ) and a p85 regulatory subunit. Activated adaptor proteins bind via YXXM motifs of PI3Ks and relieve p85-mediated inhibition of p110. This recruits p85-p110 heterodimers to their substrate, the lipid phosphatidylinositol-4,5-bisphosphate (PIP2), at the plasma membrane. PI3K (p110), then phosphorylate PIP2 to produce the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3). Phosphate and tensin homologue (PTEN), dephosphorylates PIP3 in position 3 inositol ring, thereby negatively regulating PI3K signaling outputs. Several pleckstrin homology (PH) domain-containing proteins, including SGK, PDK1 and most importantly, AKT, bind to PIP3 at the plasma membrane. The phosphorylation of AKT at Thr308 by PDK1 and at Ser473 by a complex involving mTOR/Rictor complex (mTORC2) results in full activation of this enzyme. AKT phosphorylates a host of cellular proteins including GSK3 α , GSK3 β , the FOXO transcription factors, MDM2, BAD, and p27KIP1 to facilitate survival and cell cycle entry. Additionally, AKT phosphorylates and inactivates Tuberin, a GTPase-activating protein (GAP) for the Ras homologue, Rheb. Inactivation of Tuberin allows GTP-bound Rheb to accumulate and activate the mTOR/Raptor complex (mTORC1), which ultimately regulates protein synthesis, RNA translation, cell growth, and autophagy.

Figure 2. Suppressive mechanism mediated by the PI3K-AKT-mTOR network in the tumor microenvironment. **A.** Upregulation of AKT within tumor cells as a result of PTEN mutations, or other methods of aberrant pathway activation can lead to the upregulation of

anti-apoptotic molecules and prevent tumor cells from undergoing apoptosis in response to CD8⁺ T cell-mediated assault. **B.** Additionally, some PTEN-mutant, and some PTEN wild type tumors with upregulated AKT signaling often secrete VEGF, a potent chemoattractant of MDSCs and Tregs. The presence of these cell types within tumor is negatively correlated with response to a variety of anti-cancer therapies; especially immunotherapies as they are capable of inhibiting the activity of a variety of immune cell types, particularly CD8⁺ T cells. **C.** PTEN-mutant tumours are often reported to constitutively express PD-L1, the ligand for the immune checkpoint receptor PD-1. The interaction of PD-L1 with PD-1 expressed on the surface of activated CD8⁺ T cells can induce a state of functional exhaustion and inhibit their anti-tumor activity. **D.** Immunosuppressive cytokines secreted from tumors as a result of PI3K-AKT-mTOR signaling can suppress tumor-specific CD8⁺ T cell activity (migration, proliferation and cytotoxicity). **E.** Together, these immunosuppressive effects can prevent the induction of protective immunological memory. Tem = effector memory, Tcm = central memory, Trm = tissue resident memory.

Figure 3. Rationale for combining immunotherapies with PI3K-AKT-mTOR inhibitors.

PI3K-AKT-mTOR (A) or BRAF/MEK (B) inhibitors can have both tumor cell-intrinsic and immune cell-intrinsic effects. By combining these targeted therapies with various immunotherapeutic approaches (C), it is likely that anti-tumor efficacy can be further improved.

TABLE 1 – PI3K/AKT/mTOR aberrations in main solid tumors*

| PI3K pathway aberrations | Chromosome Location | Protein Function | Histopathology (Prevalence %) |
|------------------------------------|---|---|---|
| <i>PIK3R1/2</i> mutation | PIK3R1 (5q13.1) PIK3R2 (19q13.2-q13.4) | Genes encoding p85 α and p85 β , the regulatory subunits of PI3K | Prostate: 22% Endometrial Carcinoma: 20% (PIK3R1); 5% (PIK3R2) GBM: 8-10% Breast: 2% Colorectal: < 1% Skin SCC: 11% Melanoma 1-2% |
| <i>PIK3CA</i> mutation | 3q26.3 | Gene encoding p110 α , the catalytic subunit of PI3K | Breast: 20%-50% Endometrial, ovarian: 25-30% SCLC: 20-23% HNSCC: 20% Colorectal: 14% GBM: 10% Prostate: 6% NSCLC): 5% Melanoma 3% |
| <i>PIK3CA</i> amplification | 3q26.3 | Gene encoding p110 α , the catalytic subunit of PI3K | NSCLC: 10-30% HNSCC: 20% Breast: 10% Esophageal SCC: 10% |
| <i>AKT1/2</i> amplification | AKT1 14q32.32 AKT2 19q13.1-q13.2 | Genes encoding AKT1 and 2 protein isoforms | HNSCC: 5% Breast, ovarian, pancreatic, Gastric cancer: < 5% Colorectal cancer: < 1% |

| | | | |
|-----------------------------|----------|--|--|
| <i>AKT1</i> mutation | 14q32.32 | Gene encoding for AKT1 protein isoform | Colorectal: 6% Breast (TNBC): 3% NSCLC: 1-2% Endometrial: 1% |
| <i>PTPN12</i> loss | 7q11.23 | Gene encoding the tumor suppressor PTPN12, a non-receptor tyrosine phosphatase leading to enhanced tyrosine phosphorylation of multiple growth factor receptors, that leads to PI3K pathway activation | Breast: 23% Breast (TNBC): 60% |
| <i>INPP4B</i> loss | 4q31.1 | Gene encoding INPP4B, which dephosphorylates phosphatidylinositol 3,4-bisphosphate (PI(3,4)P ₂) on the D4 position generating phosphatidylinositol 3-phosphate (PI(3)P) | Breast (TNBC): 30%-56% Lung (NSCLC): 47% Ovarian: 40% Prostate: 8% |
| <i>PTEN</i> loss | 10q23.3 | Gene coding PTEN, that negatively regulates this pathway by dephosphorylating PIP ₃ at its D3 position, thereby inhibiting downstream kinase activation | NSCLC: 75% Endometrial: 55% Ovarian: 45% Colorectal: 20%-40% Breast, HNSCC: 30% GBM: 60%-80% Prostate: 20% |
| <i>PTEN</i> mutation | 10q23.3 | Gene coding PTEN, which negatively regulates this pathway by dephosphorylating PIP ₃ at its D3 position, thereby inhibiting downstream kinase activation | Endometrial: 44% Breast: < 5% Colorectal: < 5% GBM: 5%-40% |

* PI3K-AKT-mTOR aberrations in haematopoietic malignancies is reviewed by Gao et al. [110]

| TABLE 2 - PI3K/AKT/mTOR pathway inhibitors: clinical characteristics, genomic context and toxicity | | | | |
|---|--|---|---|--|
| PI3K/AKT/mTOR pathway inhibitors | Biomarkers of response | Potential advantages | Limitation | Toxicity |
| Dual PI3K/mTOR Inhibitors [111, 112] | Tumor types with loss-of-function in the negative regulators PTEN, TSC1/2, and STK11 | Drugs with broadest activity profile | Multikinase blockade leads to increased toxicity, this class of agents may not be as well suited to combination therapy as other agents | Hyperglycemia, astenia, nausea/vomiting, diarrhea, rash, mucositis |
| Isoform-Specific PI3K Inhibitors [113, 114] | PIK3A mutation | To be investigated in selective patients according to biomarkers of response | Drugs with narrowest activity profile | α – Hyperglycemia, astenia, nausea/vomiting, diarrhea β – Astenia, nausea/vomiting, diarrhea, anemia δ – Astenia, nausea/vomiting, diarrhea, rash, liver dysfunction, pneumonitis, pyrexia, hematologic toxicities |
| AKT inhibitors [115, 116] | PTEN loss or <i>PIK3CA</i> mutations | AKT inhibition counteracts its tumor-driven immunosuppressive effects through remodeling of the tumor microenvironment and restoring T cell metabolism. | The response rate as single agent is 5% , hence combination is needed [85] | Hyperglycemia, astenia, nausea/vomiting, diarrhea, rash |
| mTORC1/2 Inhibitors [117, 118] | Unknown | mTORC1 and mTORC2 inhibition | Genomic profiling of responsive tumors has not | Hyperglycemia, astenia, nausea/vomiting, diarrhea, rash, pneumonitis, |

| | | | | |
|---|---|---|---|---|
| | | | been reported | hepatotoxicity |
| Pan-class I PI3K inhibitors [119, 120] | Tumor types that lack <i>PIK3CA</i> mutations | <p>Better suited to combination therapy than dual PI3K/mTOR inhibitors</p> <p>The efficacy of pan-PI3K inhibitors are not restricted to tumors harboring PIK3CA mutations</p> | Drugs with narrower activity profile than dual PI3K/mTORi | Hyperglycemia, astenia, nausea/vomiting, diarrhea, rash |

| TABLE 3 – Current clinical trials investigating PI3K-AKT-mTOR inhibitors in solid tumors* | | | | |
|--|--------------|--|----------------------------|---|
| Drug(s)(clinical trial number) | Phase | Histopathology | Primary Endpoint(s) | Secondary Endpoint(s) |
| Monotherapy | | | | |
| <i>PI3K inhibitors</i> | | | | |
| BYL719 (NCT02145312) | 2 | SCCHN | DCR | OR, PFS, OS, TTP, Toxicity, Safety, Quality of life |
| BKM120 (NCT01629615) | 2 | Breast cancer | Clinical benefit | PFS, OS, AEs, Safety, PK |
| BKM120 (NCT01830504) | 2 | Thyroid cancer | PFS | OR, OS, Safety |
| BKM120 (NCT01737450) | 2 | Head and neck cancer | DCR | PFS, OS, Safety, OR, DOR, TTP |
| BKM120 (NCT01806649) | 2 | Esophageal Squamous cell Carcinoma | DCR | Safety, PFS, OS |
| CUDC-907 (NCT02307240) | 1 | NUT midline carcinoma Breast cancer Solid tumors | MDT | PK, Safety, Tolerability |
| ZSTK474 (NCT01682473) | 1 | Solid tumors | DLT | PK |
| BYI719 (NCT02506556) | 2 | Breast cancer | OR | CBR, PFS, Safety, Tolerability |
| Lenvatinib (NCT02860936) | 2 | Carcinomas of the Salivary Glands | OR | PFS, OS, Safety, Tolerability, DOR |

| | | | | |
|-----------------------------|---|---|----------------------------------|--|
| PQR309 (NCT02850744) | 2 | Glioblastoma multiforme | PFS OR | AEs, SAEs, Physical examination, Depression Test, PK, DOR |
| BKM120 (NCT02128724) | 1 | NSCLC | MTD | Changes in 18F- Misonidazole uptake as detected by PET-CT scans, PK |
| <i>AKT inhibitors</i> | | | | |
| ARQ 092 (NCT01473095) | 1 | Solid Tumors Malignant Lymphoma | Safety Tolerability | PK, PD, RP2D |
| GSK2141795 (NCT00920257) | 1 | Solid Tumors Lymphoma | RP2D | Efficacy, Metabolite profile |
| MK2206 (NCT01283035) | 2 | Ovarian cancer Fallopian cancer Peritoneal Cancer | OR | OS, PFS, Toxicity |
| MK2206 (NCT01277757) | 2 | Breast cancer | OR | PFS, Median response duration, Safety |
| MK2206 (NCT01604772) | 2 | Adenoid Cyst Carcinoma | OR | PFS, OS, Toxicity |
| AZD5363 (NCT02077569) | 2 | Breast cancer | PhD | PK, Toxicity |
| MK2206 (NCT01349933) | 2 | Head and neck cancer | PFS OR | AEs, OS, PFS |
| GSK2110183 (NCT01531894) | 2 | Solid tumors Hematologic malignancies | AEs PK Vital signs | |
| MK2206 (NCT01260701) | 2 | Gastric cancer Gastroesophageal Junction | OS | PFS, OR, AEs |

| | | | | |
|---|---|-------------------------|--|--|
| | | Cancer | | |
| MK2206 (NCT01425879) | 2 | Biliary Cancer | ORR | AEs, OS, PFS |
| MK2206 (NCT01239355) | 2 | Liver cancer | PFS | OR, OS |
| MSC2363318A (NCT01971515) | 1 | Solid tumors | DLT | PD, PK, BOR, CBR, AEs |
| AZD5363 (NCT01226316) | 1 | Solid tumors | Safety Tolerability | PK, OR |
| MK-2206 (NCT01186705) | 2 | Colorectal cancer | ORR | |
| PQR 309 (NCT02483858) | 1 | Solid tumors | Safety Tolerability | DLT, PK |
| Selumetinib (NCT00888134) | 2 | Solid tumors | OR in patients with cancer other than melanoma | AKT Pathway activity, or in NSCLC and colon cancer, PFS |
| <i>mTOR inhibitors</i> | | | | |
| Everolimus (NCT01412515) | 2 | Kaposi Sarcoma | OR | |
| Everolimus (NCT01206764) | 4 | Renal cell carcinoma | PFS | ORR, OR, Safety |
| Everolimus <i>or</i> <i>or</i> Nilotinib Sorafenib <i>or</i> Lapatinib <i>or</i> Pazopanib (NCT02029001) | 2 | Solid tumors | 12-week PFS PFS | OR, OS, Safety, Quality of life |
| Combination therapy | | | | |
| <i>PI3K inhibitors</i> | | | | |
| Everolimus + Tamoxifen | 2 | Breast cancer | Clinical benefit at 24 weeks | Response, |

| | | | | |
|--|------|---------------------------|-----------------------------------|---|
| (NC T01298713) | | | | Toxicity, OS |
| Everolimus + Octreotide LAR + Metformin (NCT02294006) | 2 | pWDNETs | PFS | Safety, Tolerability, OS, OR |
| BKM120 + Erlotinib (NCT01487265) | 2 | NSCLC | PFS | DLT, OS, DOR, OR |
| BKM120 + Cetuximab (NCT01816984) | 1/2 | SCCHN | Phosphorylated (p)-EGFR MTD | Apoptosis induction, OR, OS, PFS, |
| BYL719 + Letrozole (NCT01791478) | 1 | Breast cancer | MTD | Clinical benefit, PFS, OS, OR, |
| BYL719 + AUY922 (NCT01613950) | 1 | Gastric cancer | DLT MTD | AEs, BOR, PK, ORR, PFS, OS, SAEs |
| GDC-0941 + Cisplatin (NCT01918306) | 1b/2 | Breast cancer | MTD OR | CBR, TTP |
| BKM120 + Cisplatin + Etoposide (NCT02194049) | 1 | Small cell lung cancer | AEs | MTD, OR, OS, TTP, PK |
| WX-037 +/- WX-554 (NCT01859351) | 1 | Solid tumors | DLT | AEs, SAEs, PK |
| Taselisib + Enzalutamide (NCT02457910) | 1/2 | Breast cancer | CBR MTD | PFS, OR, PK |
| BYL719 + Nab- paclitaxel (NCT02379247) | 1/2 | Breast cancer | RP2D OR | CBR, PK, PFS, OS |
| Taselisib / Pictilisib + Palbociclib (NCT02389842) | 1 | Breast cancer | RP2D Safety CBR PFS | PK |

| | | | | |
|---|------|---|----------------------------|--|
| | | | DOR | |
| Taselisib / Pictilisib + Palbociclib (NCT02389842) | 1 | Solid tumors Breast cancer | RP2D Safety Toxicity | PK |
| Copanlisib + Cetuximab (NCT02822482) | 1/2 | SCCHN | MTD RP2D | OR, OS, AEs, PK |
| GDC-0032 + Tamoxifen (NCT02285179) | 1 | Breast cancer Ovarian cancer Uterine Cancer | MDT | Safety, PK, OR |
| INC280 + Buparlisib (NCT01870726) | 1b/2 | Glioblastoma | PFS MTD | SAEs, Tolerability, PK, OR, OS |
| Letrozole +/- BYL719 <i>or</i> BKM120 (NCT01923168) | 2 | Breast cancer | pCR OR | AEs, PK |
| BKM120 + Weekly Cisplatin + Radiotherapy (NCT02113878) | 1 | SCCHN | MTD | OR, TTP, OS |
| AEB071 + BYL719 (NCT02273219) | 1 | Uveal Melanoma | MTD | AEs, PK, CBR, OS |
| Copanlisib + Trastuzumab (NCT02705859) | 1 | Breast cancer | MTD CBR | AEs/Toxicity, OS, PFS, DOR, Safety, Tolerability, TTP |
| Fulvestrant +/- Alpelisib (NCT02437318) | 3 | Breast cancer | PFS | OS, OR, Safety, Tolerability, PK, PFS |
| BKM120/ Placebo + Fulvestrant (NCT01633060) | 3 | Breast cancer | PFS | OS, OR, CBR, AEs, Overall health status |
| BKM120 <i>or</i> | 1 | Ovarian cancer | MTD | Safety, PK |

| | | | | |
|--|-----|--------------------|-------------------------------|---|
| BYL719 + Olaparib (NCT01623349) | | Breast cancer | RP2D | |
| Gedatolisib + Palbociclib + Faslodex (NCT02626507) | 1 | Breast cancer | Safety MTD | pCR |
| GSK2636771 + Paclitaxel (NCT02615730) | 1/2 | Gastric cancer | RP2D PFS | DLT |
| BKM120 + Tamoxifen (NCT02404844) | 2 | Breast cancer | PFS | OS, OR, DCR, AEs, Incidence and severity of depressive episodes |
| Taselisib/Placebo + Fulvestrant (NCT02340221) | 3 | Breast cancer | PFS | OS, OR, AEs |
| Gedatolisib + Paclitaxel + Carboplatin (NCT02920450) | 1/2 | NSCLC | DLT OR | PFS, OS, AEs |
| GSK2636771 + Enzalutamide (NCT02215096) | 1 | Prostate cancer | AEs/SAEs DLT, Safety | PK, Response |
| Enzalutamide +/- LY3023414 (NCT02407054) | 2 | Prostate Cancer | PFS | TTP, PK, OR |
| LEE011 + BYL719 + Letrozole (NCT01872260) | 1/2 | Breast cancer | DLT | Safety, AEs/SAEs, PK, OR, DOR, PFS |
| PQR309+ Eribulin (NCT02723877) | 1/2 | Breast cancer | AEs/SAEs CBR OR | TTR, DOR, PFS, TTP, PK, OS |
| LEE011 + Fulvestrant + BYL719 <i>or</i> BKM120 (NCT02088684) | 1/2 | Breast cancer | DLT PFS | Safety, Tolerability, PK, OR, DOR, OS |

| | | | | |
|--|-----|---|-------------------|---|
| INCB050465 + INCB039110 + Epacadostat (NCT02559492) | 1 | Solid tumors | DLT | OR, PFS, DOR |
| INCB050465 + Pembrolizumab (NCT02646748) | 1 | Solid tumors | Safety | OR, PFS, DOR |
| BKM120 + Trastuzumab + Paclitaxel (NCT01816594) | 2 | Breast cancer | pCR | OR, pCR, Safety |
| <i>AKT inhibitors</i> | | | | |
| GSK2141795 + Dabrafenib + Trametinib (NCT01902173) | 1/2 | Colon carcinoma Melanoma Ovarian cancer | MTD | OS, PFS, Toxicity |
| MK2206 + Dinaciclib (NCT01783171) | 1 | Pancreatic cancer | MTD | DCR, AEs, OS, PFS |
| MK2206 + Lapatinib Ditosylate (NCT01281163) | 1 | Breast cancer | MTD | Safety, PK, Response |
| MK2206 + Lapatinib Ditosylate (NCT01245205) | 1 | Breast cancer | MTD AEs | OR, PFS, DLT, PFS |
| GSK1120212 + GSK2110183 (NCT01476137) | 1 | Solid tumors Myeloma | Safety OR | PK, PFS, DOR |
| AZD5363 + Olaparib (NCT02338622) | 1 | Solid tumors | Safety MTD | PK |
| MK2206 + Selumetinib (NCT01519427) | 2 | Melanoma | OR | Changes in Biomarker Expression, PFS, OS |
| GSK2141795 + Trametinib | 2 | Breast carcinoma | OR | CBR, DOR, AEs, |

| | | | | |
|--|-----|-------------------------------|---|--|
| (NCT01964924) | | | | SAEs, PFS |
| MK2206 + Selumetinib + Fluorouracil + Oxaliplatin (NCT01658943) | 2 | Pancreatic cancer | OS | AEs, PFS, OR |
| +/- GSK2141795 + Trametinib (NCT01979523) | 2 | Uveal melanoma | TTP | Toxicity, OS, PFS, OR |
| AZD5363 + Paclitaxel (NCT02423603) | 2 | Breast cancer | PFS | |
| MK-2206 + AZD6244 (NCT01333475) | 2 | Colorectal cancer | pERK and pAKT Levels in Tumor Biopsies | AEs |
| Triciribine + Carboplatin (NCT01690468) | 1/2 | Ovarian Cancer | MTD | OR, PFS, Duration of stable disease |
| MK-2206 + Paclitaxel + Trastuzumab (NCT01235897) | 1 | HER2-positive solid tumors | MTD | BOR |
| ARQ 092 + carboplatin + paclitaxel <i>or</i> ARQ 092 + paclitaxel <i>or</i> ARQ 092 + anastrozole (NCT02476955) | 1 | Solid tumors | AEs | PK, OR, DLT |
| Afuresertib + Paclitaxel (NCT02240212) | 1 | Gastric cancer | SAEs Lab: ECG, LVEF, blood pressure, vital signs assessment | PK, PFS, SAEs, AEs |
| AZD5363 +/- docetaxel and prednisolone | 1/2 | Prostate cancer | DLT PFS | Safety, Tolerability, PK, Biochemical OR |

| | | | | |
|--|---|----------------|-------------------------------|--|
| (NCT02121639) | | | | |
| Paclitaxel +/- Ipatasertib (NCT02301988) | 2 | Breast cancer | pCR | OR, Efficacy, Safety, PK |
| Paclitaxel +/- Ipatasertib (NCT02162719) | 2 | Breast cancer | PFS | OS, OR, DOR |
| Ipatasertib + Cobimetinib (NCT01562275) | 1 | Solid tumors | DLT MTD | PK, OR, DOR, PFS |
| <i>mTOR inhibitors</i> | | | | |
| Everolimus + Sorafenib (NCT01141309) | 2 | Thyroid cancer | OR | PFS, Safety, Toxicity |
| Temsirolimus + Sorafenib (NCT01025453) | 2 | Thyroid Cancer | OR | PFS, Safety, Tolerability |
| Paclitaxel followed by FEC <i>or</i> paclitaxel+RAD001 followed by FEC (NCT00499603) | 2 | Breast cancer | Inhibition of PI3K pathway | Response |
| Temsirolimus + Letrozole <i>or</i> Letrozole (NCT00062751) | 2 | Breast cancer | OR | BOR, TTP , PFS, DOR, Health Outcomes Assessment, Population with Response |
| PF-05212384 + Docetaxel, Cisplatin <i>or</i> Dacomitinib (NCT01920061) | 1 | Solid tumors | DLT | PK, Gene sequence data, OR |
| Everolimus + Eribulin (NCT02616848) | 1 | Breast cancer | MTD | PK, Safety |
| <i>mTOR inhibitors + AKT inhibitors</i> | | | | |

| | | | | |
|--|-----|--|---------------------------|---|
| AZD2014 + AZD5363 + Olaparib (NCT02208375) | 1/2 | Endometrial cancer Ovarian Cancer | MTD | OR |
| Olaparib +/- AZD1775, AZD5363, <i>or</i> AZD2014 (NCT02576444) | 2 | Solid tumors | OR | |
| <i>mTOR inhibitors + PI3K inhibitors</i> | | | | |
| Alpelisib + Everolimus <i>or</i> Alpelisib+ Everolimus + Exemestane (NCT02077933) | 1 | Breast cancer Renal cell cancer Pancreatic neuroendocrine tumors | MTD DLT AEs | Safety, Tolerability, PFS, DOR, CBR, OR, PFS |
| MLN0128 + MLN1117 (NCT01899053) | 1 | Solid tumors | Number of AEs PK | OR, DOR |

***Source Document: Clinical Trial Gov. 2/10/2016.**

OR: Objective Response; **SCCHN:** Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck; **NSCLC:** Non small cell lung carcinoma; **NUT:** carcinomas characterized by chromosomal rearrangements that involve the gene encoding the nuclear protein of the testis (NUT); **DCR:** Disease control rate; **PFS:** Progression Free Survival; **OS:** Overall Survival; **TTP:** Time to progression; **PK:** Pharmacokinetics; **PD:** Pharmacodynamic; **pWDNETs:** well-differentiated neuroendocrine tumors; **RR:** Response rate; **RP2D:** Recommended phase 2 trial dose; **AEs:** Adverse Events; **MTD:** Maximum Tolerated Dose; **DOR:** Duration of response; **DLT:** Dose-limiting toxicity; **OR:** Overall response; **BOR:** Best Overall Response; **SAEs:** Serious Adverse Events; **CBR:** Clinical Benefit Rate; **TTP:** Time to disease progression; **pCR:** Pathological complete response; **ECOG:** Eastern Cooperative Oncology Group; **PS:** Performance status; **ECG:** Electrocardiogram; **LEVF:** Left ventricular ejection fraction; **FEC:** 5-Fluorouracil + Epirubicin + Cyclophosphamide





